文献速递MDS 与骨髓增殖性肿瘤

患者报告疲劳改善高危骨髓增生异常综合征预后:MDS-CAN研究

Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study.
PubMed 文献 · Br J Haematol · 2021-05-31

该加拿大MDS注册研究验证了FA-IPSS(h)模型,该模型结合EORTC QLQ-C30疲劳评分(阈值≥45分)与IPSS高危分层可区分不同生存亚组。

要点

  • FA-IPSS(h)模型结合EORTC QLQ-C30疲劳评分(≥45分)与IPSS高危分层,可区分不同生存亚组。
  • 自报疲劳可改善高危MDS患者的总生存预测,支持将患者报告结局纳入整体评估。

核心结论

  • 自报疲劳可改善高危MDS患者的总生存预测,支持将患者报告结局纳入整体评估。

主要发现

  • FA-IPSS(h)模型结合EORTC QLQ-C30疲劳评分(阈值≥45分)与IPSS高危分层,可将患者分为生存结局不同的亚组。

关键数值与推荐

  • FA-IPSS(h)模型中疲劳阈值:EORTC QLQ-C30评分≥45分。
  • 疲劳评估工具:EORTC QLQ-C30和ESAS全球疲劳量表(GFS)。

临床怎么用

  • 在高危MDS评估中可纳入患者自报疲劳(如EORTC QLQ-C30或ESAS GFS)以细化生存预测。
  • FA-IPSS(h)模型可用于IPSS高危患者,结合疲劳评分进行风险分层。
  • ESAS GFS单条目疲劳量表更易于临床部署,可作为疲劳评估的简化工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incorporation of patient-reported outcomes with traditional disease risk classification was found to strengthen survival prediction in patients with myelodysplastic syndromes (MDS). In the present Canadian MDS registry analysis, we validate a recently reported prognostic model, the Fatigue-International Prognostic Scoring System among higher-risk patients [FA-IPSS(h)], which incorporates patients' reported fatigue, assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30), with a threshold of ≥45 points, in higher IPSS score, stratifying them into distinct subgroups with different survival outcomes. We further validated this concept, using the Revised IPSS >3·5 as cut-off for the definition of higher-risk MDS, and patients' reported fatigue according to Edmonton Symptom Self-Assessment Scale (ESAS) Global Fatigue Scale (GFS), a single-item fatigue rating scale, which is easier to deploy. This emphasises the power of self-reported fatigue at refining overall survival predictions in higher-risk MDS and further bolsters the importance of considering patient-related outcomes in global assessments.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Amitai I, Geddes M, Zhu N, et al. Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study. Br J Haematol. 2021. PMID: 34060069. doi:10.1111/bjh.17537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。